tradingkey.logo
tradingkey.logo
Buscar

MDxHealth SA

MDXH
Añadir a la lista de seguimiento
0.507USD
+0.096+23.48%
Cierre 07/01, 16:00ETCotizaciones retrasadas 15 min
26.04MCap. mercado
PérdidaP/E TTM

Más Datos de MDxHealth SA Compañía

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

Información de MDxHealth SA

Símbolo de cotizaciónMDXH
Nombre de la empresaMDxHealth SA
Fecha de salida a bolsaJun 26, 2006
Director ejecutivoMr. Michael K. McGarrity
Número de empleados312
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 26
DirecciónCAP Business Center
CiudadHERSTAL
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísBelgium
Código postal4040
Teléfono3243642070
Sitio Webhttps://mdxhealth.com/
Símbolo de cotizaciónMDXH
Fecha de salida a bolsaJun 26, 2006
Director ejecutivoMr. Michael K. McGarrity

Ejecutivos de MDxHealth SA

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael K. McGarrity
Mr. Michael K. McGarrity
Chief Executive Officer, Director
Chief Executive Officer, Director
95.00K
--
Mr. Michael Holder
Mr. Michael Holder
Director
Director
--
--
Mr. Mark Shaffar
Mr. Mark Shaffar
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher (Chris) Thibodeau
Mr. Christopher (Chris) Thibodeau
Executive Vice President & U.S. Chief Operations Officer
Executive Vice President & U.S. Chief Operations Officer
--
--
Dr. Sanford S Siegel, M.D.
Dr. Sanford S Siegel, M.D.
Director
Director
--
--
Mr. Joseph (Joe) Sollee
Mr. Joseph (Joe) Sollee
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
Mr. John Bellano
Mr. John Bellano
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Rudi Marien
Mr. Rudi Marien
Non-Executive Director
Non-Executive Director
--
--
Mme. Ruth Devenyns
Mme. Ruth Devenyns
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Walter M. (Wally) Narajowski
Mr. Walter M. (Wally) Narajowski
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael K. McGarrity
Mr. Michael K. McGarrity
Chief Executive Officer, Director
Chief Executive Officer, Director
95.00K
--
Mr. Michael Holder
Mr. Michael Holder
Director
Director
--
--
Mr. Mark Shaffar
Mr. Mark Shaffar
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher (Chris) Thibodeau
Mr. Christopher (Chris) Thibodeau
Executive Vice President & U.S. Chief Operations Officer
Executive Vice President & U.S. Chief Operations Officer
--
--
Dr. Sanford S Siegel, M.D.
Dr. Sanford S Siegel, M.D.
Director
Director
--
--
Mr. Joseph (Joe) Sollee
Mr. Joseph (Joe) Sollee
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de MDxHealth SA?

Los cinco principales accionistas de MDxHealth SA son: Mr. Michael K. McGarrity

¿Cuántas instituciones poseen acciones de MDxHealth SA (MDXH)?

A fecha de 2026Q1, 91 instituciones poseen acciones de MDxHealth SA, con un valor de mercado combinado de aproximadamente 25.38M, lo que representa el 49.41% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -275861.00.